Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?

Table 1

Selected hematological parameters in patients with psoriasis as compared to nonpsoriatic controls and their relation to the Psoriasis Area and Severity Index (PASI).

Author, year [ref.]	Number of patients/controls	Mean/median PASI or BSA		Correlation to PASI
C-reactive protein
Chodorowska et al., 2004 [51]	175/30	29.2	↑	ND
Coimbra et al., 2010 [52]	73/38	18.0	↑	In correlation with PASI
Takahashi et al., 2014 [49]	97/79	10.6/9.2 (male/female)	↑	Not associated with PASI
Vachatova et al., 2016 [44]	74/65	Median; 15.3	↑	ND
Interleukin-6
Coimbra et al., 2010 [55]	66/37	18.8	↑	In correlation with PASI
Deeva et al., 2010 [56]	35/10	8.7	↑	Not associated with PASI
Kaur et al., 2012 [57]	58/58	9.5	↑	In correlation with PASI
Adiponectin
Coimbra et al., 2009 [54]	56/37	19.2	↓	ND
Gerdes et al., 2011 [73]	79/80	12.2	↑	Not associated with PASI
Kaur et al., 2011 [50]	60/44	10.1	NS (all patients)	ND
Li et al., 2014 [37]	122/134	Median BSA 2.9%	↓	ND
Baran et al., 2015 [43]	49/16	16.5	↓	Not associated with PASI
Vachatova et al., 2016 [44]	74/65	Median 15.3	NS	ND
LEPTIN
Gerdes et al., 2011 [73]	79/80	Median 12.2	NS	Not associated with PASI
Kaur et al., 2011 [50]	60/48	10.1	NS (all patients)	Not associated with PASI
Li et al., 2014 [37]	122/134	Median BSA 2.9%	NS	ND
Baran et al., 2015 [43]	49/16	16.5	↓	Not associated with PASI
Vachatova et al., 2016 [44]	74/65	Median; 15.3	↑	ND
Coimbra et al., 2010 [55]	66/37	18.8	↑	ND

PASI: Psoriasis Area and Severity Index. (the interpretation of PASI score differed between the studies. In most studies, the score below 10 was interpreted as mild disease, between 10 and 20 as moderate, and above 20 as severe disease.) BSA: body surface area; ↑: increased in patients; ↓: decreased in patients; NS: not significant; ND: not done; mild disease.